Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation.
BACKGROUND
Following the release of the initial presentation of filgrastim (granulocyte colony-stimulating factor), several biosimilars have been developed worldwide.


OBJECTIVE
To study the efficacy of a Mexican biosimilar granulocyte colony-stimulating factor in a single transplant center.


METHODS
In a group of 19 consecutive patients with multiple sclerosis given autografts, we employed granulocyte colony-stimulating factors to mobilize stem cells from the bone marrow to the peripheral blood, either the original granulocyte colony-stimulating factor (n = 10) or a Mexican granulocyte colony-stimulating factor biosimilar (n = 9).


RESULTS
The efficacy of both agents was similar in mobilization capacity, white blood cell count rise, stem cell collection, and kinetics of auto-engraftment.


CONCLUSIONS
We conclude that both granulocyte colony-stimulating factor agents were similar in their efficacy to mobilize stem cells and usefulness in autografts.
Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Puebla, Mexico.|Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.
Mónica
M
León-González
Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Puebla, Mexico.|Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Andrés A
AA
León-Peña
Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.|Laboratorios Clínicos de Puebla, Puebla, Mexico.
María Fernanda
MF
Vallejo-VIllalobos
Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Puebla, Mexico.|Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Ana Karen
AK
Núñez-Cortés
Laboratorios Clínicos de Puebla, Puebla, Mexico.|Universidad de las Américas Puebla, Puebla, Mexico.
Alejandro
A
Ruiz-Argüelles
Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Puebla, Mexico.|Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.|Laboratorios Clínicos de Puebla, Puebla, Mexico.|Universidad de las Américas Puebla, Puebla, Mexico.
Guillermo J
GJ
Ruiz-Argüelles
D000328:Adult; D000368:Aged; D059451:Biosimilar Pharmaceuticals / Q000008:administration & dosage*; D005260:Female; D000069585:Filgrastim / Q000008:administration & dosage*; D006401:Hematologic Agents / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008800:Mexico; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000628:therapy; D011446:Prospective Studies; D014182:Transplantation, Autologous
D059451:Biosimilar Pharmaceuticals; D006401:Hematologic Agents; D000069585:Filgrastim